MedTrace Logo

BAY2586116 Nasal Spray and OSA Severity

NCT05527457 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-02-15

No results posted yet for this study

Summary

This investigator-initiated study aims to determine the effects of BAY2586116 (a novel TASK channel blocker nasal spray) on sleep apnoea severity and the potential influence of route of breathing.

Conditions

  • Sleep Apnea, Obstructive

Interventions

DRUG

BAY2586116

160 μg BAY2586116 nasal spray application

DRUG

Placebo

Placebo (saline) nasal spray application

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Flinders University

    lead OTHER

Principal Investigators

  • Danny J. Eckert, PhD · Flinders University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-31
Primary Completion
2022-12-20
Completion
2022-12-20

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05527457 on ClinicalTrials.gov